LivaNova (LIVN) Stock Overview
A medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LIVN from our risk checks.
LIVN Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LivaNova PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.92 |
| 52 Week High | US$71.92 |
| 52 Week Low | US$35.00 |
| Beta | 0.97 |
| 1 Month Change | -7.30% |
| 3 Month Change | -10.33% |
| 1 Year Change | 60.15% |
| 3 Year Change | 24.33% |
| 5 Year Change | -29.61% |
| Change since IPO | 391.00% |
Recent News & Updates
LIVN: 2026 Core Execution And OSA Expansion Will Test Fair Value View
The analyst price target for LivaNova has been raised by a few dollars per share, with the higher range of $73 to $85 cited in connection with stronger recent results, a firmer 2026 outlook, and expectations for sustained contributions from neuromodulation and cardiopulmonary. Analyst Commentary Recent Street research on LivaNova clusters in a higher target range of about $73 to $85, with most analysts pointing to recent results, solid contributions from neuromodulation and cardiopulmonary, and management's 2026 outlook as key inputs to their updated models.LIVN: 2026 Execution In Core Segments Will Test Fair Value View
Analysts have increased the blended price target for LivaNova by several dollars into the low to mid $70s, reflecting Q4 outperformance, constructive 2026 commentary, and updated models that indicate solid contributions from both neuromodulation and cardiopulmonary segments. Analyst Commentary Recent Street commentary around LivaNova clusters around upward revisions to price targets, but the tone is not uniformly bullish.
LIVN: 2026 Setup And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova rises from about $73 to roughly $80, reflecting analysts' responses to recent Q4 results, revised models for 2026, and supportive commentary on the company's neuromodulation and cardiopulmonary performance. Analyst Commentary Recent research updates show a cluster of higher price targets for LivaNova, with analysts focusing on Q4 performance, expectations for 2026, and the contribution from neuromodulation and cardiopulmonary.Recent updates
LIVN: 2026 Core Execution And OSA Expansion Will Test Fair Value View
The analyst price target for LivaNova has been raised by a few dollars per share, with the higher range of $73 to $85 cited in connection with stronger recent results, a firmer 2026 outlook, and expectations for sustained contributions from neuromodulation and cardiopulmonary. Analyst Commentary Recent Street research on LivaNova clusters in a higher target range of about $73 to $85, with most analysts pointing to recent results, solid contributions from neuromodulation and cardiopulmonary, and management's 2026 outlook as key inputs to their updated models.LIVN: 2026 Execution In Core Segments Will Test Fair Value View
Analysts have increased the blended price target for LivaNova by several dollars into the low to mid $70s, reflecting Q4 outperformance, constructive 2026 commentary, and updated models that indicate solid contributions from both neuromodulation and cardiopulmonary segments. Analyst Commentary Recent Street commentary around LivaNova clusters around upward revisions to price targets, but the tone is not uniformly bullish.LIVN: 2026 Setup And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova rises from about $73 to roughly $80, reflecting analysts' responses to recent Q4 results, revised models for 2026, and supportive commentary on the company's neuromodulation and cardiopulmonary performance. Analyst Commentary Recent research updates show a cluster of higher price targets for LivaNova, with analysts focusing on Q4 performance, expectations for 2026, and the contribution from neuromodulation and cardiopulmonary.LIVN: Fairly Valued As 2026 Outlook Offsets Multiple Compression Risk
The updated analyst price target for LivaNova moves from a fair value estimate of $56 to about $67. Analysts point to recent price target hikes across the Street that reference Q4 outperformance, solid 2026 commentary, and expectations for consistent organic growth as key supports for the revised view.LivaNova: Excellent Performer, But Too Expensive In 2026 (Rating Downgrade)
Feb 27
LIVN: 2026 Organic Drivers And Medicare Shift Will Support Re Rating
Narrative Update on LivaNova LivaNova’s updated analyst price targets, rising by roughly $8 to $12 per share into the mid to high $60s and low $70s, reflect analysts’ use of higher target multiples in line with comparable MedTech names. They also indicate a view that organic growth will play a larger role in relative valuation from 2026 onward.LIVN: Higher 2026 Medtech Multiples And Reimbursement Shift Will Drive Re Rating
Narrative Update on LivaNova LivaNova's analyst price targets have shifted higher into a roughly mid US$60s to US$70 range. Analysts point to adjusted target multiples that align more closely with comparable MedTech names and updated views on organic growth and sector setup into 2026.LIVN: Improved Reimbursement And 2026 Reset Will Support Constructive Repricing
Narrative Update The analyst price target on LivaNova has been lifted from about US$69 to roughly US$73 as analysts factor in higher target multiples, in line with recent moves in comparable MedTech names and modestly more constructive views reflected in updated fair value, discount rate, revenue growth, profit margin and forward P/E assumptions. Analyst Commentary Recent research updates on LivaNova cluster around higher price targets and a reset in expectations for 2026, with most of the discussion focused on how the shares should trade relative to other MedTech names as fundamentals and valuation reconnect.LIVN: Higher Medtech Multiples And Reimbursement Changes Will Support Re Rating
The analyst fair value estimate for LivaNova has moved from US$80 to US$86, reflecting analysts' use of higher target P/E multiples in line with recent moves in comparable MedTech names and updated views on revenue growth and profit margins. Analyst Commentary Bullish analysts are lifting their targets for LivaNova, pointing to higher target P/E multiples that are more in line with comparable MedTech peers.LIVN: Higher Reimbursement Will Still Leave Shares Vulnerable To Multiple Compression
Analysts have modestly raised their price target on LivaNova to $56.00 per share. This reflects slightly stronger long term revenue growth and margin expectations, partially offset by a lower assumed future earnings multiple and a marginally higher discount rate.LIVN: Improved Reimbursement And Raised Guidance Will Support Measured 2025 Outlook
Analysts have modestly revised their price target for LivaNova to remain effectively unchanged at approximately 69 dollars per share. This reflects stable assumptions around revenue growth, profitability, and valuation multiples, despite only incremental tweaks to the discount rate and long term earnings expectations.Improved Revenues Required Before LivaNova PLC (NASDAQ:LIVN) Stock's 26% Jump Looks Justified
Dec 07
LIVN: Reimbursement Rate Increases And Guidance Raise Will Support 2025 Momentum
Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.LIVN: Upgraded 2025 Outlook Will Drive Confidence Amid Business Momentum
Narrative Update on LivaNova Analyst Price Target Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking
Aug 17Aging Populations And China Expansion Will Drive Device Adoption
Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).LivaNova (NASDAQ:LIVN) Has A Pretty Healthy Balance Sheet
Aug 03LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
Jul 07With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
Apr 11Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
Mar 21
Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 28We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)
Feb 25LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking
Dec 28We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 12LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 03LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
Oct 31LivaNova: Economics Should Start Making Sustained Improvements
Oct 18Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Oct 02LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
Aug 21LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
Jul 30At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
Jul 04Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?
Jun 13LivaNova: Focus Is Paying Off
May 12These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong
Apr 08Shareholder Returns
| LIVN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.6% | -5.3% | -0.2% |
| 1Y | 60.2% | -18.1% | 27.6% |
Return vs Industry: LIVN exceeded the US Medical Equipment industry which returned -15.3% over the past year.
Return vs Market: LIVN exceeded the US Market which returned 29.1% over the past year.
Price Volatility
| LIVN volatility | |
|---|---|
| LIVN Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LIVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LIVN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,300 | Vladimir Makatsaria | www.livanova.com |
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products.
LivaNova PLC Fundamentals Summary
| LIVN fundamental statistics | |
|---|---|
| Market cap | US$3.22b |
| Earnings (TTM) | -US$242.47m |
| Revenue (TTM) | US$1.39b |
2.3x
P/S Ratio-13.3x
P/E RatioIs LIVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIVN income statement (TTM) | |
|---|---|
| Revenue | US$1.39b |
| Cost of Revenue | US$443.98m |
| Gross Profit | US$944.07m |
| Other Expenses | US$1.19b |
| Earnings | -US$242.47m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | -4.43 |
| Gross Margin | 68.01% |
| Net Profit Margin | -17.47% |
| Debt/Equity Ratio | 31.4% |
How did LIVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 19:27 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LivaNova PLC is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Matthew Miksic | Barclays |
| Scott Bardo | Berenberg |